索拉非尼之外：晚期肝细胞癌的新型靶向治疗药物。
Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
机构信息
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA.
出版信息
Expert Opin Investig Drugs. 2010 May;19(5):663-72. doi: 10.1517/13543781003767426.
IMPORTANCE OF THE FIELD
The successful approval of sorafenib has greatly stimulated the development of other molecular targeted agents in advanced hepatocellular carcinoma (HCC).
AREAS COVERED IN THIS REVIEW
The aim of this review was to summarize the key data of sorafenib Phase III studies and the lessons and unanswered questions with sorafenib in HCC. It extensively updated the current ongoing studies combining sorafenib with erlotinib and other targeted agents or chemotherapy, and many molecularly targeted agents under development that inhibit angiogenesis, EGFR, and mammalian target of rapamycin (mTOR).
WHAT THE READER WILL GAIN
A comprehensive understanding of the current status of drug development of targeted agents in advanced HCC and insights into the challenges of developing these agents in HCC.
TAKE HOME MESSAGE
Sorafenib is the first and only approved agent in advanced HCC. Several Phase III studies are ongoing with other drugs in advanced HCC. Many early clinical trials are conducted to assess other molecularly targeted agents that inhibit different pathways of hepatocarcinogenesis.
重要性领域
索拉非尼的成功获批极大地促进了晚期肝细胞癌（HCC）其他分子靶向药物的研发。
本篇综述涵盖内容
本综述旨在总结索拉非尼 III 期研究的关键数据，以及索拉非尼在 HCC 中的经验和未解决的问题。文中还广泛更新了目前正在进行的联合索拉非尼与厄洛替尼和其他靶向药物或化疗的研究，以及许多正在开发的抑制血管生成、EGFR 和哺乳动物雷帕霉素靶蛋白（mTOR）的分子靶向药物。
读者将获得
全面了解晚期 HCC 靶向药物开发的现状，并深入了解在 HCC 中开发这些药物的挑战。
重要信息
索拉非尼是晚期 HCC 中首个也是唯一获批的药物。目前正在进行多项 III 期研究，评估其他药物在晚期 HCC 中的疗效。许多早期临床试验旨在评估其他抑制肝癌发生不同途径的分子靶向药物。
Zotero 插件